GlassScriptPhysician profile
Steven P Binette
NPI 1770535445
$3,220.92
in general payments reported to CMS, 2019-2025
28 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $267 · 2021: $511 · 2022: $645 · 2023: $733 · 2024: $182 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.88 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $237.58 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $220.72 | 2023-2025 | Myfembree |
| Minerva Surgical, INC | $215.93 | 2022-2023 | |
| Astellas Pharma US INC | $208.86 | 2020-2025 | Veozah |
| Aspira Women'S Health INC | $181.67 | 2022 | |
| Agile Therapeutics, INC. | $159.40 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $158.28 | 2020-2024 | Myosure Tissue Removal Device, Coolseal Generator, Acessa Provu System |
| Therapeuticsmd, INC. | $143.96 | 2019-2022 | |
| Myovant Sciences INC. | $140.17 | 2021-2022 | |
| Coopersurgical, INC. | $133.93 | 2020-2024 | Advincula Delineator Uterine Manipulator, Endosee, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $131.52 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $120.94 | 2023-2025 | |
| Organon LLC | $83.76 | 2022-2025 | Jada System |
| Roche Diagnostics Corporation | $79.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $73.74 | 2019-2022 | |
| Biogen, INC. | $34.25 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $28.70 | 2022-2023 | Slynd |
| Dexcom, INC. | $25.30 | 2025 | Dexcom G6 Transmitter |
| Gynesonics, INC. | $22.58 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Davol INC. | $16.94 | 2023 | Arista Ah Flexitip |
| Ascend Therapeutics US, LLC | $15.35 | 2021 | |
| Duchesnay USA Incorporated | $14.90 | 2019 | |
| Scynexis, INC. | $14.85 | 2022 | |
| Dysis Medical, INC. | $13.77 | 2020 | |
| Allergan, INC. | $12.63 | 2019 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Binette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.